Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
2026-07-20 17:30
•Jeff Siegel •The Motley Fool
•• ••• Axe Capital view
Biotech Buzz: Cathie Wood’s Bet on Beam Therapeutics and What It Means for Local Investors
Beam Therapeutics’ gene-editing promise is exciting but too early for South African investors to jump in.
Cathie Wood’s Ark Invest has ramped up exposure to Beam Therapeutics, a US biotech firm pioneering base editing—a gentler gene-editing alternative to CRISPR. The company boasts a healthy cash pile and a suite of clinical programs targeting nasty diseases like sickle cell anemia. But these trials are binary: success could revolutionize medicine, failure would catch investors off-guard. South African investors staring at the JSE might find this sector tempting, given local drug stocks often lack the same innovation drive. Yet, Beam is not listed locally and the rand's current volatility against the dollar adds currency risk. The USD/ZAR rate hovering around 18.5 means any rand weakness would amplify losses. If you want exposure to gene editing's promise, it’s better to stay patient and perhaps watch how companies like LyondellBasell’s pharma partners develop the industry before risking capital. this is just my opinion and not financial advice
Avoid direct exposure to Beam Therapeutics for now due to high clinical and currency risk. Instead, keep an eye on USD/ZAR movements and consider defensive JSE pharma stocks if biotech themes strengthen globally.
- BEAM
- USD/ZAR
- JSE pharma sector
- clinical trial failures for Beam Therapeutics
- rand depreciation increasing dollar-denominated losses
6/10
Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Jeff Siegel
Categories: Healthcare, Equities
Tickers: BEAM, CRSP, LLY
Sentiment: Positive - The article highlights Beam's differentiated base editing technology, multiple late-stage clinical catalysts, strong cash position ($1.21B), and runway through mid-2029. Cathie Wood's continued investment and the company's potential to create an entirely new market support a positive outlook, though clinical risks remain. Mentioned as a competitor in the gene-editing space. The article notes intensifying competition but does not provide specific analysis of CRISPR's prospects or performance.
Keywords: gene editing, base editing, biotech, clinical trials, FDA approval, sickle cell disease, alpha-1 antitrypsin deficiency, CRISPR alternative
Insights:
- BEAM: Positive: The article highlights Beam's differentiated base editing technology, multiple late-stage clinical catalysts, strong cash position ($1.21B), and runway through mid-2029. Cathie Wood's continued investment and the company's potential to create an entirely new market support a positive outlook, though clinical risks remain.
- CRSP: Neutral: Mentioned as a competitor in the gene-editing space. The article notes intensifying competition but does not provide specific analysis of CRISPR's prospects or performance.
- LLY: Neutral: Mentioned only as the parent company of Verve Therapeutics in the context of competitive gene-editing platforms. No direct analysis or sentiment provided.